Inflammatory bowel disease (IBD) is characterized by chronic, recurring inflammation of the digestive tract. Current therapeutic approaches are limited and include biologics and steroids such as anti-TNFα monoclonal antibodies and corticosteroids, respectively. Significant adverse drug effects can occur for chronic usage and include increased risk of infection in some patients. GPR4, a pH-sensing G protein-coupled receptor, has recently emerged as a potential therapeutic target for intestinal inflammation. We have assessed the effects of a GPR4 antagonist, 2-(4-((2-Ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole (GPR4 antagonist 13, also known as NE-52-QQ57) in the dextran sulfate sodium (DSS)-induced acute colitis mouse model. The GPR4 antagonist 13 inhibited intestinal inflammation. The clinical parameters such as body weight loss and fecal score were reduced in the GPR4 antagonist 13 treatment group compared to vehicle control. Macroscopic disease indicators such as colon shortening, splenic expansion, and mesenteric lymph node enlargement were all reduced in severity in the GPR4 antagonist 13 treated mice. Histopathological features of active colitis were alleviated in GPR4 antagonist 13 treatment groups compared to vehicle control. Finally, inflammatory gene expression in the colon tissues and vascular adhesion molecule expression in the intestinal endothelia were attenuated by GPR4 antagonist 13. Our results indicate that GPR4 antagonist 13 provides a protective effect in the DSS-induced acute colitis mouse model, and inhibition of GPR4 can be explored as a novel anti-inflammatory approach.
Introduction
Inflammatory bowel disease (IBD) is complex and characterized by loss of intestinal homeostasis resulting in dysregulated mucosal immune responses. Uncontrolled chronic gastrointestinal inflammation can result in severe complications of which include fistulas, stenosis, and abscesses (Blumberg, 2009; Brown and Mayer, 2007; Kaser et al., 2010) . Furthermore, IBD can have extrainstestinal manifestations such as arthritis, autoimmune chronic active hepatitis, and uveitis (Brown and Coviello, 2015) . Additionally, IBD can also increase the risk of the development of colon cancer (Mattar et al., 2011) . The current therapeutic landscape for IBD is limited and is predominately focused on symptomatic management (Chandel et al., 2015; Neurath, 2017; Su et al., 2018) .
IBD can take the form of ulcerative colitis (UC) and Crohn's disease (CrD). Each disease contains overlapping, yet distinct features. One interesting feature that has been noted in IBD is the display of reduced local intra-intestinal luminal pH in IBD patients compared to healthy controls (Barkas et al., 2013; Fallingborg, 1999; Fallingborg et al., 1990 Fallingborg et al., , 1993 Nugent et al., 2001) . It is also well documented local tissue pH can be reduced during active inflammation, predominately owing to heightened metabolic byproducts from excessive leukocyte infiltration accompanied by impaired cellular waste removal Lardner, 2001; Okajima, 2013) . These studies collectively suggest the intestinal mucosa and lumen can be acidic in IBD patients. It remains poorly investigated, however, how cellular constituents involved in the maintenance of the mucosal immune response sense altered pH in the intestine and subsequently alter function.
G-protein coupled receptors (GPCRs) are implicated in normal intestinal function as well as in pathological contribution during active IBD. One such family of GPCRs are the proton-sensing GPCRs, which consist of GPR4, GPR65 (TDAG8), and GPR68 (OGR1) (Chen et al., 2011; Dong et al., 2013b Dong et al., , 2017 Ishii et al., 2005; Justus et al., 2013 Justus et al., , 2017 Liu et al., 2010; Ludwig et al., 2003; Sanderlin et al., 2015;  https://doi.org/10.1016/j.ejphar.2019.03.038 Received 24 November 2018; Received in revised form 18 March 2019; Accepted 22 March 2019 Tomura et al., 2005; Wang et al., 2004; Yang et al., 2007) . These receptors are activated by protonation of extracellular histidine residues in acidic environments. Each of these receptors have recently been implicated in the modulation of intestinal inflammation (de Valliere et al., 2015; Lassen et al., 2016; Sanderlin et al., 2017; Wang et al., 2018) . Several studies have shown GPR4 is responsible for acidosisinduced endothelial cell inflammation and can functionally increase leukocyte adhesion with endothelial cells (Chen et al., 2011; Dong et al., 2013b Dong et al., , 2017 Tobo et al., 2015) . GPR4 genetic deletion in mice has also been shown to reduce intestinal inflammation and mucosal leukocyte infiltration in both inducible and spontaneous colitis mouse models Wang et al., 2018) . However, no efforts have been made to investigate the effects of pharmacological modulators of proton-sensing GPCRs in intestinal inflammation.
In this study, we have assessed the function and efficacy of a GPR4 antagonist, 2-(4-((2-Ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl) methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole (GPR4 antagonist 13, also known as NE-52-QQ57), within the dextran sulfate sodium (DSS)-induced acute colitis mouse model as a potential therapeutic for the remediation of intestinal inflammation. GPR4 antagonist 13 was recently developed and characterized by Novartis and shown effective following oral administration . GPR4 antagonist 13 was capable of reducing inflammation in the rat antigen-induced arthritis model, angiogenesis in the mouse chamber implant model, and inflammation-associated nociception in the rat complete Freund's adjuvant model . Furthermore, oral pharmacokinetics, GPR4 target selectivity, dosage and potency was thoroughly evaluated and GPR4 antagonist 13 was poised for further evaluation . Another study evaluated GPR4 antagonist 13 in mouse ventilatory responses and observed no obvious toxicities (Hosford et al., 2018) . Our results demonstrated that GPR4 antagonist 13 administration reduced disease severity, histopathological features, Fig. 1 . GPR4 antagonist 13 reduces clinical severity and macroscopic disease indicators of intestinal inflammation in mice. Mice were provided GPR4 antagonist 13 P.O. twice a day (b.i.d.) during experimental time course (A). Mouse body weight loss (B) and fecal blood and diarrhea scores (C) were daily measured. Mouse colon length (D-E), mesenteric lymph node expansion (F), and splenic enlargement (G) were also assessed upon tissue collection. Vehicle: N = 21 (10 male/11 female) and GPR4 antagonist 13: N = 19 (10male/9 female). Data are presented as mean ± S.E.M. and was analyzed for statistical significance using the t-test between vehicle and GPR4 antagonist 13 groups. (*P < 0.05, **P < 0.01, ***P < 0.001). Scale bar = 1 cm. inflammatory gene expression within the colon, and endothelial specific adhesion molecule expression within the inflamed intestinal tissue in the DSS-induced colitis mouse model.
Materials and methods

Dextran sulfate sodium (DSS)-induced colitis mouse model and GPR4 antagonist 13 delivery
Male and female mice ages 9-10 weeks in the C57BL/6 background were used for experiments. As previously described, mice were maintained specific pathogen free and housed in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited facility . Acute experimental colitis was induced by the addition of 3% (w/v) Dextran Sulfate Sodium Salt (DSS) ad libitum into the normal drinking water of mice (36,000-50,000 M.Wt, Lot# Q5229, MP Biomedical, Solon, OH). Mice were provided normal pelleted diet ad libitum during experimentation (ProLab, 2000; Purina Mills, St. Louis, MO) . Mice were treated for seven days with 3% DSS with replacement of the 3% DSS solution every two days. As previously described, during each day of the experimental course clinical parameters for disease severity were assessed . Mice were weighed for body weight loss evaluation and feces was assessed for fecal blood and diarrhea using the Hemoccult Single Slides screening test (Beckman Coulter, Brea, CA). For GPR4 antagonist 13 administration, the small molecule (> 99% purity) was suspended in 0.5% methylcellulose/0.5% Tween 80/99% water and a dosage of 30 mg/kg (b.i.d.) was given to mice as previously described . This dosage was chosen based on our previous testing of increasing doses (3, 10 and 30 mg/kg) of which the best efficacy was observed with 30 mg/kg . Furthermore, the toxicity studies performed during the development of the compound showed no hepatopathy. On day one, mice were orally gavaged with either vehicle or 30 mg/kg GPR4 antagonist 13 in the morning followed by addition of 3% DSS into the drinking water and another dose of GPR4 antagonist 13 or vehicle in the afternoon. On days two through six, mice were orally gavaged with vehicle or GPR4 antagonist 13 twice a day (b.i.d.). On day seven mice were euthanized for tissue collection and macroscopic disease indicator measurement (Fig. 1A ). Mice were dissected as previously described and mesenteric lymph node expansion, colon shortening, and splenic expansion were measured .
Sample collection for histology and molecular analysis
Following the completion of the seven-day DSS treatment, mice were euthanized and tissue was collected for histology and molecular analysis. The spleen and liver were resected and weighed for assessment of expansion. The mesenteric lymph nodes were identified using a dissection microscope, measured for volume calculation, and stored in 10% buffered formalin as previously described ). The gastrointestinal tract was then removed from the mouse and the colon was separated from the cecum at the ileocecal junction. Next, the colon content was removed by PBS flushing and opened along the antimesenteric border. Colon tissue approximately 1 mm in width was removed from the anus to proximal colon. This tissue was then cut into thirds for distal, middle, and proximal colon segments and promptly snap frozen in liquid nitrogen for molecular analysis. The remaining colon segment was fixed in 10% buffered formalin (VWR) and cut into thirds as distal, middle, and proximal colon segments for histological analysis.
Histopathological analysis
Distal, middle, proximal colon segments, and liver tissues were fixed in 10% buffered formalin, embedded in paraffin and sectioned at 5 μm thickness. Slides were then stained with hematoxylin and eosin (H&E) for histopathological analysis. Colon segments were evaluated by operators blind to sample identification according to previously published criteria with minor modifications (Erben et al., 2014) . Briefly, each colon segment was evaluated in four recurring locations. Each location was evaluated for leukocyte infiltration, epithelial damage, and mucosal architecture distortions. The leukocyte infiltration score included severity scores of 1 = mild, 2 = moderate, and 3 = severe with regard to both degree and location of cellular infiltrates. The mucosal architecture score included 1 = focal epithelial erosions, 2 = focal ulcerations, and 3 = extended ulcerations. The sum score of these parameters represents the histopathological score of colitis severity. Liver tissues were evaluated for histological indicators of drug-induced toxicity.
RNA collection and real time RT-PCR
Total RNA was collected from the distal colon segments using the IBI Scientific DNA/RNA/Protein extraction Kit (MidSci, St. Louis, MO). 500 ng of RNA was reversed transcribed using SuperScript IV and diluted 1:10 in ultrapure water (Gibco, Gaithersburg, MD). TaqMan predesigned primer-probe sets used for the evaluation of specific gene expression (Applied Biosystems, Waltham, MA). TaqMan primer-probe sets and subsequent assay ID include 18S rRNA; (Hs99999901_s1),
TNF-α; (Mm00443258_m1), IL-10; (Mm01288386_m1), and IL-6; (Mm00446190_m1). Real-time PCR was performed in duplicate with a program of 50°C for 2 min, 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Data was acquired using the QuantStudio 3 Real-Time PCR system and analyzed using the 2 -ΔCt method.
Immunohistochemistry
Immunohistochemistry (IHC) was performed as previously described . Briefly, serial 5 μm paraffin-embedded sections of distal, middle, and proximal colon segments were deparaffinized and hydrated to water. Antigen retrieval was then performed using Tris-EDTA pH 9.0 with 0.1% Tween 20. Following endogenous peroxidase blocking and AVIDIN/BIOTIN block (Invitrogen, Carlsbad, CA), tissue sections were incubated with primary antibodies against VCAM-1 (Abcam, ab134047, 1:100, Cambridge, MA), MAdCAM-1 (Abcam, ab90680, 1:500, Cambridge, MA), TNF-α (Bioss, bs-2081R, 1:1000, Woburn, MA) or E-selectin/CD62E (Abcam, ab18981, 1:1000, Cambridge, MA) overnight at 4°C. The rat or rabbit VECTASTAIN Elite ABC HRP kit was then used according to the manufactures protocol (Vector Laboratories, Burlingame, CA). The ImmPACT DAB (Vector Laboratories, Burlingame, CA) substrate was utilized for signal detection. Slides were then dehydrated and mounted. Pictures were taken with the Zeiss AxioImager.M2 with Axiocam 503 digital color camera.
Blood vessel VCAM-1 and E-selectin intensity score and MAdCAM-1 positive vessel enumeration
After IHC was performed for VCAM-1 and E-selectin on colon tissue segments, VCAM-1 and E-selectin intensity was blindly assessed by two independent operators from distal, middle, and proximal segments. Scoring criteria included 1 = none/minimal, 2 = mild, 3 = moderate, and 4 = high signal intensity. Each tissue segment was completely evaluated using 10x and 20x objectives and subsequently scored for intensity. For MAdCAM-1 positive vessel enumeration, vessels were assessed from the distal, middle, and proximal colon segments and total MAdCAM-1 positive vessels were counted using 10x and 20x objectives. The total colon length was recorded in centimeters and results were shown as MAdCAM-1 positive vessels/centimeter.
Statistical analysis
GraphPad Prism software was utilized for all statistical analysis. Results were recorded as the mean ± standard error. When analysis was performed between two groups the unpaired t-test or MannWhitney test was utilized. All comparisons P < 0.05 are considered statistically significant where * P < 0.05, **P < 0.01, and ***P < 0.001.
Results
GPR4 antagonist 13 reduces the severity of colitis in the acute DSSinduced colitis mouse model
Wild-type C57BL/6 mice were initiated on the acute DSS colitis model and given vehicle or 30 mg/kg of GPR4 antagonist 13 b.i.d. by oral gavage (Fig. 1A) . During each day of the experimental course mouse body weight in conjunction with fecal blood and diarrhea scores were evaluated to provide clinical assessment of disease severity Fig. 2 . GPR4 antagonist 13 reduces histopathological parameters of intestinal inflammation in the inflamed mouse colon. Distinct histopathological features of intestinal inflammation were assessed and scored for degree of severity. Representative pictures of vehicle distal (A), Middle (C), and proximal (E) colon segments compared to GPR4 antagonist 13 distal (B), middle (D), and proximal (F) colon segments. Graphical representation of total histopathological parameters (G) and leukocyte infiltration score (H). Vehicle: N = 21 (10 male/ 11 female) and GPR4 antagonist 13: N = 19 (10male/9 female). Data are presented as mean ± S.E.M. and was analyzed for statistical significance using the t-test between vehicle and GPR4 antagonist 13 groups between each colon segment. (*P < 0.05, **P < 0.01, ***P < 0.001). 10x objective. Scale bar = 100 μm.
between vehicle and GPR4 antagonist 13 groups. GPR4 antagonist 13 treated mice were protected from body weight loss commencing from day five through seven (Fig. 1B) . Mice given vehicle lost 11-14% body weight by day seven while mice provided GPR4 antagonist 13 lost between 5 and 6% body weight. Fecal blood and diarrhea scores provided further indication GPR4 antagonist 13 protects against intestinal inflammation as mouse fecal scores were reduced in GPR4 antagonist 13 treated mice compared to vehicle (Fig. 1C) . Fecal blood and diarrhea could be observed in mice with progressive severity from day one through seven. Vehicle mice developed heighted fecal scores earlier than GPR4 antagonist 13 treated mice and maintained more severe scores throughout the seven-day DSS experiment. These results collectively provide evidence GPR4 antagonist 13 can blunt the clinical severity of DSS-induced intestinal inflammation. Fig. 3 . GPR4 antagonist 13 reduces VCAM-1 protein expression in colon microvascular endothelial cells. VCAM-1 protein expression intensity was assessed by immunohistochemistry (IHC) in colon microvascular endothelial cells. Representative pictures of vehicle distal (A), middle (C), and proximal (E) colon segments compared to GPR4 antagonist 13 distal (B), middle (D), and proximal (F) colon segments followed by graphical representation of VCAM-1 intensity score (G). Vehicle: N = 21 (10 male/11 female) and GPR4 antagonist 13: N = 19 (10male/9 female). Data are presented as mean ± S.E.M. and was analyzed for statistical significance using the t-test between vehicle and GPR4 antagonist 13 groups between each colon segment. (**P < 0.01). 40x objective. Scale bar = 100 μm. Black arrows indicate blood vessels.
Clinical severity and macroscopic disease indicators are reduced in mice treated with GPR4 antagonist 13
Upon completion of the final day of the acute colitis mouse model, mice were dissected for assessment of macroscopic disease indicators such as colon shortening, mesenteric lymph node expansion, and splenic expansion. We observed that mice treated with GPR4 antagonist 13 had reduced colon shortening when compared to vehicle (colon length ∼7.3 cm versus ∼6.1 cm, respectively) ( Fig. 1D and E) . Mesenteric lymph nodes (MLNs) were also collected, and the volume was measured in vehicle and GPR4 antagonist 13 treated mice. Vehicle MLN volume was expanded by more than 2-fold when compared to GPR4 antagonist 13 mice (Fig. 1F) . These results indicate GPR4 antagonist 13 reduces colonic inflammation and associated expansion of MLNs when compared to vehicle. Finally, the spleen to body weight ratio was assessed in vehicle and GPR4 antagonist 13 DSS-treated mice. We observed reduced splenic expansion in mice treated with GPR4 antagonist 13 when compared to vehicle suggesting reduced disease severity due to GPR4 inhibition (Fig. 1G) . Furthermore, liver weight was assessed for indicators of drug-induced liver toxicity. No differences in liver gross morphology or weight between vehicle and GPR4 antagonist 13 treated mice were observed (Supplemental Fig. 1 ).
GPR4 inhibition reduces histopathological features in mouse colon
To assess the effects of GPR4 inhibition at the histological level, distinct pathological cellular features of colitis were assessed in the distal, middle, and proximal colon segments. Some such features assessed in the colon were leukocyte infiltration, epithelium erosion, crypt distortion, and mucosal ulceration. In both vehicle and GPR4 antagonist 13 DSS-treated mice, the highest degree of histopathology can be observed in the distal colon segments followed by the middle and proximal, respectively. The observation that intestinal inflammation is most severe in the distal colon within the DSS model are consistent with literature (Chassaing et al., 2014; Kim et al., 2012; Laroui et al., 2012; Perse and Cerar, 2012) . When comparing vehicle and GPR4 antagonist 13 mouse groups, the degree of histopathology was significantly reduced by GPR4 antagonist 13 when compared to vehicle ( Fig. 2A-G) . This GPR4 antagonist 13-mediated reduction in histopathology occurred in both the distal and middle colon segments (P < 0.01) with a trend in reduction at the proximal segment, though not statically significant. Interestingly, the degree of leukocyte infiltration was also reduced by GPR4 antagonist 13 when compared to vehicle (Fig. 2H) . Liver tissues were also assessed for drug-induced liver pathologies. No overt histopathological features could be observed (Supplemental Fig. 1 ).
Endothelium specific VCAM-1 and E-selectin expression are reduced by GPR4 antagonist 13
Previous studies have demonstrated GPR4 activation in endothelial cells (ECs) induces vascular cell adhesion molecule-1 (VCAM-1) and Eselectin expression (Chen et al., 2011; Dong et al., 2013b; Tobo et al., 2015) . Additionally, reports have shown GPR4 genetic deletion can reduce VCAM-1 and E-selectin expression in the vascular endothelium . Here we assessed the protein expression signal intensity of VCAM-1 and E-selectin of intestinal microvascular endothelial cells in the distal, middle, and proximal colon mucosa segments of vehicle and GPR4 antagonist 13 DSS-treated mice (Figs. 3 and  4) . The intensity scoring of VCAM-1 and E-selectin expression revealed highest signal within the distal intestinal endothelia with progressive intensity reduction from the middle and proximal colon, respectively. These data are consistent with the observation of reduced leukocyte infiltration in the middle and proximal colon segments compared to the distal segment (Fig. 2H) . Interestingly, VCAM-1 and E-selectin signal intensity in intestinal microvascular ECs was reduced in GPR4 antagonist 13 DSS-treated mice when compared to vehicle in the distal colon and a trend of reduction in the middle colon (Figs. 3 and 4) . Collectively, these data provide evidence GPR4 antagonist 13 reduces EC activation and subsequently leukocyte infiltration into the inflamed intestinal mucosa.
Immunohistochemical analysis also revealed expression of VCAM-1 and E-selectin on cell types not regulated by GPR4. VCAM-1 expression could be strongly observed in activated fibroblasts and other mononuclear cells within the intestinal mucosa (Supplemental Figs. 2A and  2B ). Previous reports have observed expression of VCAM-1 in skeletal muscle, fibroblast, and some leukocyte populations (Epperly et al., 2002; Ulyanova et al., 2005) . E-selectin expression could be detected within the colon epithelium (Supplemental Figs. 2C and 2D) . These results are consistent with previous studies showing E-selectin can be expressed on the colon epithelium and in mononuclear cells in the intestinal mucosa during active colitis (Vainer et al., 1998) . Furthermore, additional studies have shown E-selectin is expressed in T cells and can be upregulated by pro-inflammatory mediators (Bajnok et al., 2017; Harashima et al., 2001) . We observed similar levels of signal intensity of VCAM-1 and E-selectin in cell types other than intestinal microvascular endothelial cells between vehicle and GPR4 antagonist 13 groups (Supplemental Fig. 2) .
In addition to VCAM-1 and E-selectin expression analysis, we assessed the expression intensity and distribution of mucosal vascular addressin cell adhesion molecule-1 (MAdCAM-1) in colon tissues. We observed prominent MAdCAM-1 expression in intestinal microvasculature with high expression density in the lamina propria (Fig. 5) . No MAdCAM-1 expression could be observed in arteries and extramural blood vessels and minimal expression could be detected in lymphatic endothelial cells. MAdCAM-1 expression signal intensity in the intestinal microvasculature were similar between vehicle and GPR4 antagonist 13 DSS-treated mouse groups ( Fig. 5A and B) . Total number of vessels positive for MAdCAM-1, however, were markedly reduced in GPR4 antagonist 13 mice compared to vehicle control mice (Fig. 5A-D) . Total MAdCAM-1 positive vessels were counted per centimeter (cm) from the entire length of the colon. Vehicle treated mice had ∼60 MAdCAM-1 positive vessels/cm compared to ∼35 MAdCAM-1 positive vessels/cm in GPR4 antagonist 13 treated mice (Fig. 5E ).
Inflammatory gene expression is reduced in the distal colon by GPR4 antagonist 13
Following the assessment of histopathology and endothelial cellspecific inflammatory protein expression, we assessed inflammatory gene expression at the whole tissue level to discern the anti-inflammatory effects of GPR4 antagonist 13. Inflammatory genes were measured from the distal colon segment of vehicle and GPR4 antagonist 13 DSS-treated mice. Additionally, distal colon segments of wild-type mice not treated with DSS were collected and assessed to serve as a baseline gene expression reference. Inflammatory mediators such as TNF-α, IL-1β, IL-6, IL-10, and PTGS2 (COX-2) were measured between vehicle and GPR4 antagonist 13 groups (Fig. 6) . A statistically significant reduction of TNF-α and IL-10 gene expression could be appreciated in the GPR4 antagonist 13 group compared to vehicle. Reduction of TNF-α is correlated with reduced inflammation in the mouse distal colon of the GPR4 antagonist 13 group. We also assessed TNF-α protein expression in the distal colon by immunohistochemical analysis. An appreciable reduction of TNF-α expression could be observed in immune cell infiltrates and endothelial cells within GPR4 antagonist 13 treated mice compared to vehicle control (Supplemental Fig. 3 ). Contrary to TNF-α, IL-10 can inhibit the function of macrophages and other inflammatory cells which are required for optimal pathogen clearance and subsequent inflammatory resolution (Couper et al., 2008; Kessler et al., 2017; Rojas et al., 2017) . As such, reduced levels of IL-10 mRNA in the tissues of GPR4 antagonist 13 treated mice could potentially enhance pathogen clearance during the acute inflammatory phase.
Furthermore, vehicle administered mice also had a trend in heighted expression of the inflammatory genes IL-1β and IL-6 when compared to the GPR4 antagonist 13 treated group. In addition to inflammatory cytokines, adhesion molecule gene expression including E-selectin, MAdCAM-1, and VCAM-1 were assessed. A statistically significant reduction of MAdCAM-1 expression could be discerned in the GPR4 antagonist 13 treated mice compared to vehicle (Fig. 6B) . These results are in line with reduced MAdCAM-1 positive vessels in the distal colon of GPR4 antagonist 13 mice compared to vehicle (Fig. 5) . VCAM-1 gene expression was modestly reduced in the GPR4 antagonist 13 group compared to vehicle and no trend in reduction could be discerned for Eselectin at the whole tissue level (Fig. 6D and F) . As VCAM-1 and Eselectin are expressed in cells that are not regulated by GPR4 (Supplemental Fig. 2) , whole tissue gene expression analysis presents complications for assessing VCAM-1 and E-selectin expression specific to GPR4 regulated vascular endothelial cells. To overcome this complication, we assessed VCAM-1 and E-selectin protein expression specific to vascular endothelial cells as described above (Figs. 3 and 4) . Fig. 4 . GPR4 antagonist 13 reduces E-selectin protein expression in colon microvascular endothelial cells. E-selectin protein expression intensity was assessed by IHC in colon microvascular endothelial cells. Representative pictures of vehicle distal (A), middle (C), and proximal (E) colon segments compared to GPR4 antagonist 13 distal (B), middle (D), and proximal (F) colon segments followed by graphical representation of E-selectin intensity score (G). Vehicle: N = 21 (10 male/11 female) and GPR4 antagonist 13: N = 19 (10male/9 female). Data are presented as mean ± S.E.M. and was analyzed for statistical significance using the t-test between vehicle and GPR4 antagonist 13 groups between each colon segment. (**P < 0.01). 40x objective. Scale bar = 100 μm. Black arrows indicate blood vessels.
Taken together, the results indicate that GPR4 antagonist 13 reduces inflammatory gene expression in the distal colon of DSS-treated mice.
Discussion
The local pH of the inflammatory tissue is characteristically acidic. The contribution to reduced tissue pH during active inflammation is predominately owing to the heavy influx of immune cells to sites of inflammation and hypoxia (Lardner, 2001; Okajima, 2013) . The pH within these tissue microenvironments can fluctuate within the physiological range to severely acidic. Furthermore, some groups have evaluated the pH within gastrointestinal tract of patients with active IBD (Fallingborg et al., 1993; Nugent et al., 2001 ). These reports suggest the intraluminal colonic pH can be altered in patients with active colitis. Molecular mechanisms for sensing extracellular pH during intestinal inflammatory responses have only recently been investigated. The pH-sensing GPCRs, including TDAG8 (GPR65), OGR1 (GPR68), and GPR4, have emerged as regulators of intestinal inflammation ( Initial studies on the effects of acidic pH-induced activation of GPR65 have provided an anti-inflammatory role for GPR65 in macrophages, among other immune cell populations, during inflammation (Jin et al., 2014; Mogi et al., 2009 ). Furthermore, genetic variances within the GPR65 gene were correlated to increased risk of the development of a variety of inflammatory diseases of which include inflammatory bowel disease (Barrett et al., 2009; Beecham et al., 2013; Cortes et al., 2013; Franke et al., 2010; Hardin et al., 2014; Jostins et al., 2012; Karnes et al., 2014; Okada et al., 2014; Sawcer et al., 2011) . These data implicate pH homeostasis and cellular pH sensing mechanisms in the regulation of inflammation. A recent study investigated GPR65 in a bacteria-induced colitis model and found GPR65 protects against intestinal inflammation (Lassen et al., 2016) . GPR68 has also been investigated and found to potentiate intestinal inflammation through regulating macrophage inflammatory programs in response to acidic pH (de Valliere et al., 2015) . Finally, GPR4 has been studied in both acute and chronic intestinal inflammation mouse models Wang et al., 2018) . Previous reports indicate GPR4 is predominately expressed in vascular endothelial cells (ECs) (Chen et No difference in MAdCAM-1 protein expression intensity was observed between vehicle and GPR4 antagonist 13 colon microvascular endothelial cells; however, differences in total number of MAdCAM-1 positive vessels were observed between the two treatment groups. Representative pictures of vehicle distal (A, C) compared to GPR4 antagonist 13 (B, D) . Graphical representation of MAdCAM-1+ blood vessels per colon centimeter are depicted (E). Vehicle: N = 21 (10 male/11 female) and GPR4 antagonist 13: N = 19 (10male/9 female). Data are presented as mean ± S.E.M. and was analyzed for statistical significance using the t-test between vehicle and GPR4 antagonist 13 groups. (***P < 0.001). 20x and 40x objective. Black arrow indicates microvasculature, purple arrow indicates lymphatic endothelial cell, yellow arrow indicates artery. Scale bar = 100 μm.
expression was evaluated within normal and inflamed mouse colon tissues and was found to be predominately expressed within intestinal ECs . Several studies implicate GPR4 as a regulator of EC activation in response to extracellular acidosis by increasing vascular adhesion molecules such as VCAM-1, E-selectin, and ICAM-1 and functionally increasing EC-leukocyte interactions (Chen et al., 2011; Dong et al., 2013b; Tobo et al., 2015) . Previous studies have implicated these mechanistic insights into mouse colitis models. We have previously demonstrated genetic deletion of GPR4 in mice reduced intestinal inflammation in an acute DSS-induced colitis mouse model . Additionally, GPR4 knockout (KO) mice had reduced neutrophil, macrophage, and T cell infiltration into the intestinal mucosa. The reduced leukocyte infiltration was associated with GPR4-dependant reduction of vascular adhesion molecule expression in the intestinal ECs. Another group assessed the functional role of GPR4 in chronic DSS-induced inflammation and the IL-10 KO spontaneous colitis mouse model . Mice devoid of GPR4 had reduced intestinal inflammation and subsequent mucosal CD4 + T helper cell infiltration. These studies collectively suggest GPR4
mediates intestinal inflammation through increasing gut leukocyte recruitment and subsequent extravasation into the intestinal mucosa. Inhibition of GPR4 may be explored as a novel anti-inflammatory Fig. 6 . GPR4 antagonist 13 reduces inflammatory gene expression in the distal colon. Tissue level gene expression of cytokines, adhesion molecules, and an inflammatory enzyme were assessed in the distal colon segment of DSS-treated mice given vehicle or GPR4 antagonist 13. Graphical representation of TNF-α (A), MAdCAM-1 (B), IL-10 (C), VCAM-1 (D), IL-1β (E), E-selectin (F), IL-6 (G), and PTGS2 (H) gene expression. Vehicle: N = 21 (10 male/11 female) and GPR4 antagonist 13: N = 19 (10male/9 female). Data are presented as mean ± S.E.M. and was analyzed for statistical significance using the MannWhitney test between vehicle and GPR4 antagonist 13 groups between each colon segment. (*P < 0.05, **P < 0.01). Dotted black line are indicative of untreated control C57Bl/6 mice (N = 2 male/2 female).
approach. In this study we show that the GPR4 antagonist 13 can reduce intestinal inflammation in the DSS-induced acute experimental colitis mouse model. Upon initiation of DSS-induced colitis, mice provided 30 mg/kg of the GPR4 antagonist 13 b.i.d. during the 7-day colitis insult were protected from body weight loss, fecal blood and diarrhea, colon shortening, mesenteric lymph node expansion, and splenic enlargement. Colon histopathology was also alleviated in mice given the GPR4 antagonist. Following the observation of reduced leukocyte infiltration in GPR4 antagonist-treated mice, coupled with previous reports showing that GPR4 can stimulate vascular adhesion molecule expression in vitro and in vivo, we performed immunohistochemistry to evaluate the protein expression of VCAM-1, E-selectin, and MAdCAM-1 specific to the cell type regulated by GPR4, namely, ECs within the intestinal microvasculature. A notable reduction of VCAM-1 and E-selectin expression in ECs as well as a reduced number of MAdCAM-1 positive microvessels were observed within the distal colon segments of mice given the GPR4 antagonist compared to vehicle. These observations suggest that the GPR4 antagonist 13 reduces the expression of vascular adhesion molecules on ECs and thus attenuates leukocyte-endothelium adhesion and extravasation (Fig. 7) .
Upon immunohistochemical evaluation of VCAM-1 and E-selectin within the colon, notable expression could also be detected in cell types not known to be regulated by GPR4. VCAM-1 could be observed on fibroblasts, macrophages, and other mononuclear cells within the colon. These observations are supported by several other studies describing basal and inflammation-associated VCAM-1 upregulation on activated fibroblasts and inflammatory cells (Epperly et al., 2002; Ulyanova et al., 2005) . Studies have also observed E-selectin expression is not restricted to the vascular endothelium as E-selectin can be expressed by the colonic epithelium, mononuclear cells of which can include T cells (Bajnok et al., 2017; Harashima et al., 2001; Vainer et al., 1998) . Our results were consistent with these reports as E-selectin could be detected in colonic epithelial cells and mononuclear cell populations within the inflamed mucosa (Supplemental Fig. 2) . Notably, the expression of VCAM-1 and E-selectin in fibroblasts, colonic epithelial cells and mononuclear cells was at a similar level in the colon of GPR4 antagonist 13 and vehicle treated mice. These observations may explain why the mRNA expression levels of VCAM-1 and E-selectin in the whole colon tissue were either just slightly reduced or not changed in the mice treated with GPR4 antagonist 13 compared to vehicle as these cell types are not regulated by GPR4.
In addition to vascular adhesion molecules, the expression of TNF-α and IL-10 was also significantly reduced in the distal colon tissue of mice given the GPR4 antagonist when compared to vehicle. TNF-α and IL-10 mRNA reduction at the whole tissue level is most likely due to the reduction of inflammatory cells into the colon observed in the GPR4 antagonist 13 treated mice. Increased IL-10 mRNA levels are commonly observed in the acute DSS-induced colitis mouse model and in mucosal T cells of patients with active ulcerative colitis (Egger et al., 2000; Melgar et al., 2003) . GPR4 antagonist 13-mediated reduction of IL-10 mRNA is in line with reduced leukocyte infiltration. Furthermore, as mentioned above, reduced IL-10 mRNA levels could aid optimal pathogen clearance and subsequent inflammatory resolution and enhance pathogen clearance during the acute inflammatory phase (Couper et al., 2008; Kessler et al., 2017; Rojas et al., 2017) . A modest reduction of IL-1β and IL-6 could also be observed in mice treated with the GPR4 antagonist. Collectively, these results implicate GPR4 inhibitors as novel anti-inflammatory agents for colitis-associated intestinal inflammation.
GPR4 inhibitors have proved effective in the reduction of endothelial inflammation and subsequent tissue inflammation in vitro and in vivo, respectively (Dong et al., 2013a Fukuda et al., 2016; Fig. 7 . Model of proposed mechanism of the anti-inflammatory action of GPR4 inhibitors. GPR4 activation by protons in the extracellular milieu mediates the activation of vascular endothelial cells, the recruitment of immune cells and subsequent leukocyte extravasation into the inflamed tissue. Heavy immune cell infiltration into the inflammatory loci will result in further production of protons, as well as pro-inflammatory mediators, and subsequently maintain tissue inflammation and GPR4 activation. Inhibition of GPR4 activity by pharmacological intervention may present a novel approach to reduce inflammation by attenuating vascular endothelial cell activation and leukocyte infiltration into inflamed tissues. Hosford et al., 2018; Miltz et al., 2017; Sanderlin et al., 2015; Tobo et al., 2015; Velcicky et al., 2017) . A group of imidazo-pyridine and pyrazolopyrimidine derivatives were previously found to elicit inhibitory effects on GPR4-mediated EC activation (Dong et al., 2013a Hosford et al., 2018; Miltz et al., 2017; Tobo et al., 2015; Velcicky et al., 2017) . Further studies revealed this class of compounds could reduce mortality events in a myocardial infraction mouse model (Fukuda et al., 2016) . Recently, the imidazo-pyridine derivatives were further characterized as an orally active GPR4 antagonist 39c . This compound is commercially available and used to provide proof of concept in the pro-inflammatory role of GPR4 in endothelial inflammation (Dong et al., 2013b . However, due to offtarget effects such as cross-reactivity with the histamine H 3 receptor, GPR4 antagonist 39c was not further pursued Velcicky et al., 2017) . Finally, the GPR4 antagonist 13, a pyrazolopyrimidine derivative, was developed and evaluated . Common off-targets, such as the H3 receptor and hERG channel, were evaluated for GPR4 antagonist 13 binding and the compound proved selective to the GPR4 receptor. In vivo pharmacokinetic studies proved GPR4 antagonist 13 had good profiles of oral exposure and low clearance. Additionally, an in vitro safety profile assessment for GPR4 antagonist 13 against a panel of receptors, enzymes, and ion channels indicated GPR4 antagonist 13 did not significantly inhibit these targets. Therefore, GPR4 antagonist 13 was assessed in several animal models and was found to inhibit inflammation as well as hyperplasia and angiogenesis in vivo . Taken together, the optimized GPR4 antagonist 13 displays a good pharmacological profile and has proven orally active for in vivo use. Nonetheless, there are some aspects requiring close attention for the use of GPR4 inhibitor for anti-inflammatory effects.
Previous studies have shown that a fraction of GPR4 knockout mice display vascular abnormalities associated with mouse perinatal complications (Yang et al., 2007) . GPR4-null mice also exhibit decreased renal acid excretion (Sun et al., 2010) . Other reports have shown GPR4 is expressed in retrotrapezoid nucleus (RTN) neurons and is involved CO 2 chemosensing to regulate breathing (Kumar et al., 2015) . A recent study evaluated the central nervous system (CNS) effects of GPR4 antagonist 13 and observed no effects on hemodynamics, blood oxygen levels, and cerebral blood flow (Hosford et al., 2018) . However, GPR4 antagonist 13 reduced hypercapnic response to CO 2 but had no effect when mice were under anesthesia. These studies suggest that current GPR4 inhibitors have a good overall pharmacological profile but might not be taken during pregnancy or if renal and respiratory complications exist.
Taken together, this study is the first to evaluate the effects of the pharmacological inhibition of GPR4 on intestinal inflammation. We have shown that GPR4 antagonization can reduce the degree of intestinal inflammation in the DSS-induced acute experimental colitis mouse model. Further studies need to be done to evaluate GPR4 inhibition in other diseases characterized by dysregulated inflammation. Additional efforts are also needed to develop and evaluate new classes of GPR4 inhibitors for further pharmacological characterization. 
